Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repurposing Ivermectin for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL)
NCT07286604Phase 1Completed
- Sponsor
- icddr,b
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHILD-IVITAB in Post kala-azar dermal leishmaniasis (PKDL), sponsored by icddr,b. Primary endpoints: Number of Severe Adverse Events in Participants at 3 months and Number of Participants with Negative PCR Results at 12 months. Started Mar 2022; status: completed.
02
Drugs
CHILD-IVITAB
03
Conditions
Post kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on NCT07286604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07286604.